Edition:
India

AcelRx Pharmaceuticals Inc (ACRX.OQ)

ACRX.OQ on NASDAQ Stock Exchange Global Market

3.25USD
2:29am IST
Change (% chg)

$-0.03 (-0.91%)
Prev Close
$3.28
Open
$3.30
Day's High
$3.39
Day's Low
$3.22
Volume
444,784
Avg. Vol
455,926
52-wk High
$5.05
52-wk Low
$1.65

Chart for

About

AcelRx Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain. Its lead product... (more)

Overall

Beta: 1.77
Market Cap(Mil.): $203.06
Shares Outstanding(Mil.): 61.91
Dividend: --
Yield (%): --

Financials

FDA approves AcelRx Pharma's opioid pain drug

The U.S. Food and Drug Administration on Friday approved AcelRx Pharmaceuticals Inc's opioid-based treatment for pain to be used under strict medical supervision, with the agency's chief highlighting reasons for the approval in a rare move.

03 Nov 2018

UPDATE 2-U.S. FDA approves AcelRx Pharma's opioid pain drug

Nov 2 The U.S. Food and Drug Administration on Friday approved AcelRx Pharmaceuticals Inc's opioid-based treatment for pain to be used under strict medical supervision, with the agency's chief highlighting reasons for the approval in a rare move.

03 Nov 2018

AcelRx Pharma's opioid pain drug gets U.S. FDA nod

Nov 2 The U.S. Food and Drug Administration on Friday approved AcelRx Pharmaceuticals Inc's opioid-based pain treatment, a fast-acting pill.

02 Nov 2018

AcelRx shares surge after FDA staff says opioid safe

AcelRx Pharmaceuticals Inc's shares surged 30 percent on Wednesday after U.S. Food and Administration staff said the company's opioid treatment was safe and effective, bringing it one step closer to a marketing approval.

10 Oct 2018

UPDATE 2-AcelRx shares surge after FDA staff says opioid safe

Oct 10 AcelRx Pharmaceuticals Inc's shares surged 30 percent on Wednesday after U.S. Food and Administration staff said the company's opioid treatment was safe and effective, bringing it one step closer to a marketing approval.

10 Oct 2018

Earnings vs. Estimates